(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 29.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Nurix Therapeutics's revenue in 2025 is $54,549,000.On average, 7 Wall Street analysts forecast NRIX's revenue for 2025 to be $4,918,831,704, with the lowest NRIX revenue forecast at $4,173,774,935, and the highest NRIX revenue forecast at $6,070,945,360. On average, 6 Wall Street analysts forecast NRIX's revenue for 2026 to be $6,865,783,881, with the lowest NRIX revenue forecast at $4,173,774,935, and the highest NRIX revenue forecast at $15,890,699,480.
In 2027, NRIX is forecast to generate $9,015,505,633 in revenue, with the lowest revenue forecast at $5,074,551,453 and the highest revenue forecast at $15,329,137,034.